LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Search

Sanofi

Închisă

43.19 -0.02

Rezumat

Modificarea prețului

24h

Curent

Minim

42.99

Maxim

43.29

Indicatori cheie

By Trading Economics

Venit

2.4B

1.6B

Vânzări

-961M

11B

P/E

Medie Sector

19.885

49.8

EPS

1.102

Marjă de profit

14.354

Angajați

74,846

EBITDA

-1.1B

2.7B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+22.37% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-11B

104B

Deschiderea anterioară

43.21

Închiderea anterioară

43.19

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Sanofi Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 apr. 2026, 06:12 UTC

Câștiguri

Sanofi Posts Higher Sales Amid Leadership Transition

12 feb. 2026, 12:40 UTC

Principalele dinamici ale pieței

Sanofi Shares Fall After CEO Change

7 mai 2026, 06:47 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

29 apr. 2026, 12:01 UTC

Câștiguri

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 apr. 2026, 09:32 UTC

Market Talk
Câștiguri

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 apr. 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 apr. 2026, 05:34 UTC

Câștiguri

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 apr. 2026, 05:34 UTC

Câștiguri

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 apr. 2026, 05:34 UTC

Câștiguri

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 apr. 2026, 05:34 UTC

Câștiguri

Sanofi Backs 2026 View

23 apr. 2026, 05:33 UTC

Câștiguri

Sanofi 1Q Business Net Pft EUR2.26B

23 apr. 2026, 05:33 UTC

Câștiguri

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 apr. 2026, 05:33 UTC

Câștiguri

Sanofi 1Q Business Oper Pft EUR2.97B

23 apr. 2026, 05:32 UTC

Câștiguri

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 apr. 2026, 05:32 UTC

Câștiguri

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 apr. 2026, 05:31 UTC

Câștiguri

Sanofi 1Q Net Sales EUR10.51B

10 apr. 2026, 11:12 UTC

Market Talk

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 apr. 2026, 10:54 UTC

Market Talk

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 mar. 2026, 10:40 UTC

Market Talk

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 mar. 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 mar. 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 feb. 2026, 14:00 UTC

Achiziții, Fuziuni, Preluări

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 feb. 2026, 08:21 UTC

Market Talk

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 feb. 2026, 15:20 UTC

Câștiguri

Sanofi Shares Fall After CEO Change -- Update

10 feb. 2026, 14:07 UTC

Achiziții, Fuziuni, Preluări

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 feb. 2026, 14:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 feb. 2026, 14:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi Completes Acquisition of Dynavax

10 feb. 2026, 14:00 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 feb. 2026, 12:35 UTC

Câștiguri

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 ian. 2026, 13:00 UTC

Market Talk
Câștiguri

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Comparație

Modificare preț

Sanofi Așteptări

Obiectiv de preț

By TipRanks

22.37% sus

Prognoză pe 12 luni

Medie 53 USD  22.37%

Maxim 57 USD

Minim 50 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

3 ratings

0

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.665 / 52.38Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat